vidarabine phosphate has been researched along with fludarabine phosphate in 207 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 41 (19.81) | 18.7374 |
| 1990's | 89 (43.00) | 18.2507 |
| 2000's | 57 (27.54) | 29.6817 |
| 2010's | 17 (8.21) | 24.3611 |
| 2020's | 3 (1.45) | 2.80 |
| Authors | Studies |
|---|---|
| Cabanillas, F; Hagemeister, FB; Keating, MJ; McLaughlin, P; Plunkett, WK; Redman, JR; Rodriguez, MA; Swan, F; Velasquez, WS | 1 |
| Betcher, DL; Burnham, N | 1 |
| Erslev, AJ; Kane, GC; McMichael, AJ; Patrick, H | 1 |
| Benson, AB; Blough, R; French, S; Greenberg, A; Johnson, P; Kilton, LJ; Shapiro, C; Weidner, L | 1 |
| Nightingale, SL | 2 |
| Alexanian, R; Kantarjian, HM; Keating, MJ; Koller, CA; Kurzrock, R | 1 |
| Nelson, JA; Platsoucas, CD; Priebe, T | 1 |
| Ahmed, T; Arlin, Z; Arnold, P; Chun, H; Feldman, E; Mittelman, A; Puccio, C; Savona, S; Sullivan, P | 1 |
| Dahlberg, S; Eyre, HJ; Hartstock, RJ; Von Hoff, DD | 1 |
| Fox, FE; Nelson, JA; Platsoucas, CD; Priebe, T; Seki, H | 1 |
| Bonnet, JD; Crowley, JJ; Grever, MR; Hynes, HE; Keppen, MD; Kraut, EH; Salmon, SE | 1 |
| Schilling, PJ; Vadhan-Raj, S | 1 |
| Adams, JD; Chun, HG; Kummet, TD; List, AF | 1 |
| Chubb, S; Huang, P; Plunkett, W | 1 |
| Mehta, AB; Smith, OP | 1 |
| Chitambar, CR; Lundberg, JH | 1 |
| Nelson, JA; Priebe, T; Ruiz, L | 1 |
| Cheson, BD | 3 |
| Grever, MR; Malspeis, L; Staubus, AE; Young, D | 1 |
| Gandhi, V; Huang, P; Plunkett, W | 1 |
| Von Hoff, DD | 1 |
| Balcerzak, S; Grever, M; Kraut, E; Leiby, J; Malspeis, L; Metz, E; Neidhart, J | 1 |
| Keating, MJ | 1 |
| Cassileth, P; Hochster, H | 1 |
| Kantarjian, HM; Keating, MJ; Redman, JR | 1 |
| Alberts, DS; Green, S; Hannigan, EV; Surwit, EA; Von Hoff, DD | 1 |
| Avramis, VI; Champagne, J; Ettinger, LJ; Finkelstein, J; Hammond, GD; Holcenberg, JS; Krailo, M; Poplack, DG; Reaman, G; Sato, J | 1 |
| Cervantes, F; Montserrat, E; Rozman, C; Salgado, C | 1 |
| Cheson, BD; Chun, HG; Leyland-Jones, B | 1 |
| Childs, CC; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; McCredie, KB; O'Brien, S; Schachner, J; Talpaz, M | 1 |
| Catapano, CV; Chandler, KB; Fernandes, DJ | 1 |
| Chun, HG; Kraut, EH | 1 |
| Fletcher, WS; Kempf, RA; Kish, JA; Kopecky, K; Muggia, FM; Samson, MK; Von Hoff, DD | 1 |
| Alberts, DS; Green, S; Miller, TP; Stephens, RL; Stock-Novack, DL; Surwit, EA; Von Hoff, DD | 1 |
| Bastion, Y; Bryon, PA; Coiffier, B; Espinouse, D; Tigaud, JD | 1 |
| Catovsky, D; Davis, CL; Lister, TA; Mehta, AB; Ranson, M; Rohatiner, AZ; Rule, S; Smith, OP; Whelan, JS | 1 |
| Crowley, J; Eyre, HJ; Guy, JT; Hynes, HE; Jaeckle, KA; Taylor, SA; Townsend, JJ; Vogel, FS | 1 |
| Ahmed, T; Arlin, ZA; Arnold, PM; Budman, DR; Coleman, M; Feldman, EJ; Lichtman, SM; Mittelman, A; Puccio, CA; Silver, RT | 1 |
| Büchner, T; Essink, M; Freund, M; Hiddemann, W; Ottensmeier, C; Rottmann, R; Thiel, A; van de Loo, J; Wörmann, B | 1 |
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Bauman, J; Fernandez, M; Keating, M; Kemena, A; Plunkett, W | 1 |
| Casper, ES; Kelson, D; Mittelman, A; Young, CW | 1 |
| Bigner, DD; Friedman, HS; Schold, SC | 1 |
| Bodey, GP; Kavanagh, JJ; Krakoff, IH | 1 |
| Berman, E; Warrell, RP | 1 |
| Copeland, LJ; Gershenson, DM; Kavanagh, JJ; Saul, P; Stringer, CA | 1 |
| Alfieri, AA; Fuks, Z; Kim, JH; Kim, SH | 1 |
| Gaskill, HV; Phillips, JL; Weiss, GR | 1 |
| Ajani, JA; Baker, FL; Gershenson, D; Kavanagh, JJ; Spitzer, G; Thielvoldt, D; Tomasovic, B | 1 |
| Belt, RJ; Coltman, CA; Costanzi, JJ; Crowley, J; Hynes, HE; Taylor, SA; Von Hoff, DD; Weiss, GR | 1 |
| Clark, G; Hersh, MR; Kuhn, JG; Ludden, TM; Phillips, JL; Von Hoff, DD | 1 |
| Kufe, DW; Mayer, RJ; Schoene, W; Spriggs, DR; Stopa, E | 1 |
| Caryk, SM; Chun, HG; Hoth, DF; Leyland-Jones, BR | 1 |
| Carpenter, JT; Raney, M; Vogel, CL; Wang, G | 1 |
| Griffin, NL; Kagan-Hallet, K; Merkel, DE; Von Hoff, DD | 1 |
| Cabanillas, F; Danhauser, L; Keating, M; Plunkett, W | 1 |
| Grever, MR; Kraut, EH; Leiby, JM; Malspeis, L; Metz, EN; Snider, KM | 1 |
| Balducci, L; Blumenstein, B; Bukowski, RM; Crawford, ED; Davis, M; Hynes, HE; Von Hoff, DD | 1 |
| Baker, LH; Pazdur, R; Samson, MK | 1 |
| Bluestein, M; Garewal, H; Greenberg, BR; Habib, MP; Hurst, PG; Paquin, M | 1 |
| Beltran, G; Fleming, TR; Harvey, WH; Oishi, N; Saiers, JH; Von Hoff, DD | 1 |
| Metch, B; Saiers, JH; Taylor, SA; Von Hoff, DD; Weiss, GB | 1 |
| Coltman, CA; Fleming, TR; Harvey, WH; Katterhagen, JG; Von Hoff, DD | 1 |
| Alberts, DS; Hutton, JJ; Kronmal, R; O'Toole, RV; Surwit, EA; Von Hoff, DD | 1 |
| Grever, MR; Leiby, JM; Malspeis, L; Neidhart, JA; Staubus, AE | 1 |
| Ahmed, T; Arlin, Z; Arnold, P; Ashikari, R; Mittelman, A; Savona, S | 1 |
| Crowley, J; Hill, JB; Rainey, JM | 1 |
| Abbruzzese, JL; Ajani, JA; Blackburn, R; Boman, BM; Faintuch, JS; Levin, B | 1 |
| Brown, LD; Cascino, TL; Dinapoli, RP; Everson, LK; Marschke, RF; Morton, RF; O'Fallon, JR | 1 |
| Clark, GM; Diehl, V; Lathan, B; von Hoff, DD | 1 |
| Balcerzak, SP; Coltman, CA; Files, JC; Greenberg, BR; Grever, MR; Hutton, JJ; Kopecky, KJ; Talley, R; Von Hoff, DD | 1 |
| Kantarjian, H; Keating, MJ; McCredie, KB; Redman, J; Talpaz, M | 1 |
| Barlogie, B; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; McCredie, KB; Plunkett, W; Redman, J; Talpaz, M; Velasquez, W | 1 |
| Avramis, VI | 1 |
| Blough, RR; Cobleigh, MA; Kilton, LJ; Lad, TE; Shevrin, DH; Vogelzang, NJ; Weidner, LL | 1 |
| Gandhi, V; Keating, MJ; Nowak, B; Plunkett, W | 1 |
| Arteaga, CL; Brown, TD; Craig, JB; Harman, GS; Havlin, KA; Koeller, JM; Kuhn, JG; Von Hoff, DD; Weiss, GR | 1 |
| Arteaga, CL; Brown, TD; Craig, JB; Harman, GS; Koeller, JM; Kuhn, JG; Von Hoff, DD; Weiss, GR | 1 |
| Avramis, VI; Plunkett, W | 1 |
| Clark, G; Hersh, M; Hutton, JJ; Kuhn, J; Phillips, J; Von Hoff, DD | 1 |
| Boldt, DH; Hersh, M; Kuhn, JG; Von Hoff, DD | 1 |
| Drewinko, B; Hug, V; Spitzer, G; Thames, H; Umbach, GE | 1 |
| Kraut, EH | 1 |
| Cabanillas, F; Dimopoulos, M; Estey, E; Gandhi, V; Kantarjian, H; Keating, MJ; Kemena, A; O'Brien, S; Plunkett, W; Robertson, LE | 1 |
| Alexanian, R; Dimopoulos, MA; Kantarjian, H; Keating, M; Weber, DM | 1 |
| Charan, N; Crowley, JJ; Knight, L | 1 |
| Ashenhurst, JB; Benson, AB; Blough, RR; French, SL; Kilton, LJ; Schilsky, RL; Shiomoto, G; Wade, JL | 1 |
| Rodriguez, G | 1 |
| Balcerzak, SP; Benedetti, J; Dakhil, SR; Grever, MR; Miller, TP; Taylor, SA | 1 |
| Michaeli, J; Niesvizky, R; Siegel, D | 1 |
| Appelbaum, FR; Chapman, RA; Elias, L; Godwin, JE; Grever, MR; Head, DR; Metz, EN; Stock-Novack, D; Weick, JK | 1 |
| Keating, MJ; Robertson, LE | 1 |
| Binet, JL | 1 |
| Gerrits, WB; Haak, HL; Wijermans, PW | 1 |
| Shepherd, KE | 1 |
| Cabanillas, F; Dimopoulos, M; Gandhi, V; Gregoire, V; Kantarjian, H; Keating, MJ; McLaughlin, P; O'Brien, S; Robertson, LE; Yang, LY | 1 |
| Athan, E; Fein, S; Fiedor, PS; Goodman, ER; Hardy, MA; Sung, RS | 2 |
| Aboulafia, DM; Demirer, T | 1 |
| Bastion, Y; Bordessoule, D; Bosly, A; Brice, P; Brousse, N; Caspard, H; Dupas, B; Fort, N; Haïoun, C; Harousseau, JL; Leporrier, M; Morel, P; Plassart, F; Sebban, C; Solal-Céligny, P; Tilly, H; Vasile, N | 1 |
| Abassi, ZA; Carter, A; Green, J; Nakhoul, F | 1 |
| Athan, E; Fein, S; Fiedor, PS; Goodman, ER; Hardy, MA | 1 |
| Astrow, AB | 1 |
| Nikko, AP; Pandya, AG; RutherFord, CJ | 1 |
| Angelopoulou, MA; Boussiotis, VA; Kontopidou, F; Pangalis, GA; Poziopoulos, C | 1 |
| Jacobs, P; Pillay, GS; Wood, L | 1 |
| Fraternale, A; Magnani, M; Rossi, L | 1 |
| Misztal, G; Paw, B | 1 |
| Begleiter, A; Liliemark, JO; Plunkett, W; Reed, JC | 1 |
| Keating, MJ; McLaughlin, P; Robertson, LE | 1 |
| Albo, C; Benítez, E; Constenla, MI; Plaza, J; Poderós, C | 1 |
| Cheson, BD; Chun, HG; Fallavollita, A; Sorensen, JM; Vena, DA | 1 |
| Faber, E; Heczko, M; Hubácek, J; Indrák, K; Jarosová, M; Papajík, T; Pikalová, Z; Raida, L; Slezák, P; Sulovská, I | 1 |
| Allan, PW; Bennett, LL; Gilbert, KS; Gillespie, GY; King, SA; Montgomery, JA; Parker, WB; Secrist, JA; Sorscher, EJ; Waud, WR; Wells, AH | 1 |
| Alcaraz, L; Bay, JO; Béal, D; Chollet, P; Cure, H; Fouassier, M; Plagne, R; Travade, P | 1 |
| Bayle, C; Bendahmane, B; Bennaceur, A; Bosq, J; Carde, P; Decaudin, D; Hayat, M; Munck, JN; Nedellec, G; Tertian, G; Venuat, AM | 1 |
| Andreeff, M; Brown, W; Consoli, U; DiRaimondo, F; El-Tounsi, I; Kleine, HD; Plunkett, W; Robinson, JR; Sandoval, A; Snell, V | 1 |
| Filangeri, M; Morabito, F; Oliva, B; Sculli, G | 1 |
| Frankenberg, D; Hess, CF; Laurent, D; Pradier, O; Rave-Fränk, M; Schmidberger, H | 1 |
| Bosanquet, AG | 1 |
| Barbui, T; Coiffier, B; Foran, JM; Hiddemann, W; Johnson, SA; Lister, TA; Norton, AJ; Radford, JA; Rohatiner, AZ; Tollerfield, SM; Wilson, MP | 1 |
| Abdulkadyrov, KM; Beresneva, IA; Gershanovich, ML; Medvedeva, NV; Samuskevich, IG; Zaritskiĭ, AIu | 1 |
| Arima, N; Mizoguchi, H; Ohno, R; Shirakawa, S; Takatsuki, K; Tomonaga, M | 1 |
| Cullen, MH; de Takats, PG; Foran, JM; Johnson, SA; Klein, M; Kraus, C; Lister, TA; Orchard, J; Oscier, D; Tighe, M | 1 |
| Bergmann, J; Brachwitz, H; Langen, P; Thomas, Y; Wollny, T | 1 |
| Hodohara, K; Imamura, M; Kobayashi, S; Miyawaki, S; Mizoguchi, H; Ohnishi, K; Ohno, R; Tango, T; Tomonaga, M | 1 |
| Clauvel, J; Coppo, P; Ferchal, F; Lassoued, K; Scieux, C | 1 |
| Amir, G; Or, R; Polliack, A; Tejman, S; Weiss, L | 1 |
| Akutsu, M; Bai, L; Furukawa, Y; Ichikawa, A; Kano, Y; Kon, K; Suzuki, K; Tsunoda, S | 1 |
| Child, JA; Johnson, PW; Johnson, SA; Morgan, GJ; Prentice, AG; Rule, S; Smith, GM; Tollerfield, SM; Wareham, E | 1 |
| Brown, KR; Chen, S; Choi, BY; Lin, ZY; Skalski, V | 1 |
| Brandi, G; Casabianca, A; Celeste, AG; Chiarantini, L; Fraternale, A; Magnani, M; Tonelli, A; Vallanti, G | 1 |
| Cabanillas, F | 1 |
| Buckingham, L; Petersen, KS; Plate, JM; Schofield, CM; Shahidi, H | 1 |
| Plunkett, W; Sampath, D | 1 |
| Autrand, C; Binet, JL; Boudjerra, N; Cazin, B; Chastang, C; Chevret, S; Desablens, B; Dighiero, G; Divine, M; Dreyfus, B; Feugier, P; Jaubert, J; Leporrier, M; Maloum, K; Rapp, MJ; Travade, P | 1 |
| Binet, JL; Boogaerts, MA; Bosch, F; Catovsky, D; Feremans, W; Klein, M; Kovacs, M; Marcus, R; Montillo, M; Van Hoof, A; Verhoef, G; Zinzani, PL | 1 |
| Gandhi, V; Plunkett, W | 1 |
| Culligan, D; Cunningham, D; Gieschen, H; Johnson, S; Klein, M; Orchard, JA; Oscier, D; Parker, A | 1 |
| Kontoyiannis, DP; Samonis, G | 1 |
| Bennetts, E; Both, GW; Madden, V; Martiniello-Wilks, R; Russell, PJ; Smith, K; Voeks, D | 1 |
| Guo, Z; Hering, B; Heuss, N; Kirchhof, N; Levay-Young, B; Sozen, H; Sutherland, DE; Wu, T | 1 |
| Greenberg, HE; Rossoff, LJ; Stoica, GS | 1 |
| Bewsher, CJ; Braylan, RC; Hei, DL; Hudson, JK; Lynch, JW; Mendenhall, NP; Rimzsa, LM; Staab, EV | 1 |
| Budman, DR; Cascella, P; D'Amico, P; Eisenberg, P; Etcubanas, E; Ferrer, JM; Hinderling, PH; Lichtman, SM; Melikian, A; Musgrave, K; O'Mara, V; Williams, GJ; Zervos, G | 1 |
| Auzerie, V; Brouet, JC; Bussel, A; Chiali, A; Dubertret, L; Fermand, JP; Senet, P | 1 |
| Blazar, BR; Guo, Z; Hering, BJ; Heuss, N; Kalscheuer, H; Pan, Y; Sozen, H; Sutherland, DE; Wu, T | 1 |
| Avramis, IA; Avramis, VI; Laug, WE; Sausville, EA | 1 |
| Esumi, T; Ichioka, N; Iida, H; Ikehara, S; Inaba, M; Kushida, T | 1 |
| Both, GW; Dane, A; Jeyakumar, G; Martiniello-Wilks, R; Mortensen, E; Russell, PJ; Shaw, JM; Voeks, DJ; Wang, XY | 1 |
| Bernengo, MG; Fierro, MT; Quaglino, P; Rossotto, GL; Savoia, P | 1 |
| Maeda, A; Matsushita, A; Nagai, K; Oida, T; Sugimoto, N; Takahashi, T; Watanabe, N; Yanai, M | 1 |
| Berthou, C; Bron, D; de Boeck, K; Deconinck, E; Foussard, C; Guibon, O; Johnson, SA; Kramer, MH; Lister, TA; Littlewood, TJ; Marcus, RE; Montillo, M; Rossi, JF; Tollerfield, SM; van Hoof, A | 1 |
| Czarnik, AC; Dai, Y; Grant, S; Kramer, LB; Maggio, SC; Paik, DS; Payne, SG; Rahmani, M; Rosato, RR; Spiegel, S | 1 |
| Zinzani, PL | 1 |
| Both, GW; Cameron, F; Cooke-Yarborough, C; Coulston, N; Ho, T; Lockett, TJ; Martiniello-Wilks, R; Moghaddam, M; Molloy, PL; Russell, PJ; Shaw, JM; Smith, IK; Wang, XY; Webster, LK | 1 |
| Allan, PW; Bebok, Z; Hong, JS; Levasseur, DN; McPherson, SA; Moore, BA; Parker, WB; Secrist, JA; Sorscher, EJ; Townes, TM; Waud, WR; Wen, H | 1 |
| Both, GW; Dane, A; Martiniello-Wilks, R; Mortensen, E; Russell, PJ; Shaw, JM; Voeks, DJ; Wang, XY | 1 |
| Castro, JE; Eldering, E; Evers, LM; Grummels, A; Hooijbrink, B; Kater, AP; Kipps, TJ; Kramer, MH; Mackus, WJ; van Lier, RA; van Oers, MH | 1 |
| Kaplow, R | 1 |
| Abali, H; Aksoy, S; Dinçer, M; Erman, M; Kilickap, S | 1 |
| Bosanquet, AG; Daniel, PT; Dörken, B; Hummel, M; Sturm, I | 1 |
| Chie, I; Fukagawa, S; Fukuda, R; Hotta, T; Kawada, H; Kojima, S; Ogawa, Y; Onizuka, M; Shimada, M; Suzuki, R; Takagi, A; Urano, T; Yanagi, H | 1 |
| Buy, E; Cany, L; Eghbali, H; Guibon, O; Hoerni, B; Kind, M; Monnereau, A; Soubeyran, I; Soubeyran, P | 1 |
| Hotta, T; Minami, H; Morishima, Y; Ogawa, Y; Ogura, M; Sasaki, Y; Seriu, T; Tobinai, K; Watanabe, T | 1 |
| Hayashi, M; Hotta, T; Ishizawa, K; Matsuno, Y; Matsusako, M; Minami, H; Mori, S; Morishima, Y; Nakamura, S; Nawano, S; Ogawa, Y; Ogura, M; Ohashi, Y; Seriu, T; Taniwaki, M; Terauchi, T; Tobinai, K; Utsunomiya, A; Watanabe, T | 1 |
| Bachert, P; Port, CR; Port, RE; Schuster, C | 2 |
| Burnett, A; Dasgupta, RK; Davies, J; Jackson, G; Johnson, P; Morgan, GJ; Poynton, C; Richardson, C; Rule, S; Smith, GM; Stars, AC; Tollerfield, SM; Wareham, E; Wilson, K | 1 |
| de Wolf-Peeters, C; Eghbali, H; Hagenbeek, A; Hoskin, PJ; Kalmus, J; MacLennan, K; Marcus, R; Monfardini, S; Negrouk, A; Schott, A; Staab-Renner, E; Teodorovic, I; van Glabbeke, M; Vitolo, U | 1 |
| Catovsky, D; Dearden, C; Kochethu, G; MacConkey, C; Matutes, E; Milligan, DW | 1 |
| Bretonnet, AS; Cros, E; Dumontet, C; Gagnieu, MC; Galmarini, CM; Jordheim, LP; Krimm, I; Lancelin, JM | 1 |
| Biedermann, HG; Bretzel, G; Büttner, DW; Frosch, M; Hamperl, WD; Heldwein, K; Laregina, D; Löscher, T; Tappe, D | 1 |
| Bochner, BH; Cordon-Cardo, C; Kasahara, N; Kikuchi, E; Logg, CR; Menendez, S; Ohori, M; Ozu, C | 1 |
| Arndt, S; Aschendorff, A; Maier, W; Richter, B; Schmitt-Gräff, A; Veelken, H | 1 |
| Christiansen, H; Hermann, RM; Lucke, EM; Nitsche, M; Peters, K; Pradier, O; Rave-Frank, M; Schmidberger, H | 1 |
| Bénichou, J; Cazin, B; Delmer, A; Divine, M; Dreyfus, B; Dumontet, C; Eghbali, H; Feugier, P; Grosbois, B; Guibon, O; Jaubert, J; Leleu, X; Leporrier, M; Leprêtre, S; Mahé, B; Maloisel, F; Maloum, K; Tournilhac, O; Travade, P | 1 |
| Bagley, RG; Crawford, J; Krumbholz, R; Kurtzberg, LS; Lovett, D; Roth, S; Rouleau, C; Schmid, S; Teicher, BA; Yao, M | 1 |
| Artz, A; De Lima, M; Giralt, S; Kunavakkam, R; Oran, B; Rondon, G; van Besien, K | 1 |
| Huggett, B | 1 |
| Anasetti, C; Blough, DK; McCune, JS; O'Donnell, PV; Salinger, DH; Sandmaier, BM; Vicini, P | 1 |
| Greenblatt, DJ; Karyagina, EV; Lister-James, J; Lundberg, AS; Yin, W | 1 |
| Kami, M; Narimatsu, H; Oiso, G; Ono, S | 1 |
| Ishibashi, T; Iwai, K; Maeda, A | 1 |
| Brunstein, CG; Cao, Q; Green, KG; Jacobson, PA; Long-Boyle, JR; McGlave, PB; Miller, JS; Rogosheske, J; Wagner, JE; Weisdorf, DJ | 1 |
| Chen, TC; Hong, JS; Kasahara, N; Lai, YH; Li, YF; Logg, CR; Parker, WB; Sorscher, EJ; Tai, CK; Wang, W | 1 |
| Biagiotti, S; De Marco, C; Dominici, S; Magnani, M; Orlotti, N; Pierigè, F; Rossi, L; Serafini, S; Zaffaroni, N | 1 |
| Bashey, A; Baxter-Lowe, LA; Farag, S; Isola, L; Johnson, J; Kelly, M; Linker, C; McCarty, J; Owzar, K; Shea, T; Westervelt, P | 1 |
| Allan, PW; Hong, JS; Parker, WB; Sorscher, EJ; Waud, WR | 2 |
| Dunleavy, K; Figg, WD; Grant, ND; Jaffe, ES; Janik, JE; Marti, GE; Steinberg, SM; Stetler-Stevenson, M; Tohnya, T; White, T; Wilson, WH | 1 |
| Deeg, HJ; Furlong, T; Heimfeld, S; McCune, JS; O'Donnell, PV; Storer, B; Wang, J; Woodahl, EL | 1 |
| Guo, J; Kong, Y; Li, L; Liu, P; Lv, N; Spencer, DM; Tang, J; Wang, X; Wei, W; Xiao, X; Xie, GX; Xie, X; Xie, Z; Yang, M | 1 |
| Bemer, MJ; McCune, JS; O'Donnell, PV; Sandmaier, BM; Sorror, M | 1 |
| Godwin, AK; Hirst, JJ; Ma, Y; Pessetto, ZY; von Mehren, M; Weir, SJ | 1 |
| Anasetti, C; Mager, DE; McCune, JS; O'Donnell, PV; Salinger, DH; Sandmaier, BM; Vicini, P | 1 |
| Jeavons, M; Lehouritis, P; McCarthy, FO; Stanton, M; Tangney, M | 1 |
| Chen, J; Hao, Y; Patra, P; Song, S; Yang, X | 1 |
| Appelhans, D; Gorzkiewicz, M; Jatczak-Pawlik, I; Klajnert-Maculewicz, B; Pułaski, Ł; Studzian, M; Voit, B | 1 |
| Afkhami, M; Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Cao, T; Forman, SJ; Khaled, S; Marcucci, G; Mei, M; Mokhtari, S; Nakamura, R; O'Donnell, M; Pillai, R; Pullarkat, V; Salhotra, A; Snyder, D; Stein, AS; Yang, D; Yang, L | 1 |
| Carlesso, A; Chevet, E; Chintha, C; Doultsinos, D; Eriksson, LA; Paton, AW; Paton, JC; Samali, A | 1 |
| Cen, S; Dong, D; Guo, F; Guo, S; Li, Q; Li, X; Liu, Q; Liu, Z; Ma, L; Wei, T; Yi, D; Zhang, Y; Zhao, J | 1 |
| Alli, N; Balagopal, A; Bautista, M; Bhanumathy, KK; Dahiya, DK; Elhasasna, H; Freywald, A; Khan, R; Krishnan, A; Maranda, V; Patel, H; Vizeacoumar, FJ; Vizeacoumar, FS; Walke, P | 1 |
24 review(s) available for vidarabine phosphate and fludarabine phosphate
| Article | Year |
|---|---|
Metabolism and action of fludarabine phosphate.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Deamination; DNA Replication; Humans; Methylation; Molecular Sequence Data; Mutagens; Phosphorylation; Vidarabine Phosphate | 1990 |
Phase I clinical trials with fludarabine phosphate.
Topics: Animals; Antimetabolites, Antineoplastic; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Humans; Neoplasms; Vidarabine Phosphate | 1990 |
Fludarabine phosphate in the treatment of chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Prednisone; Remission Induction; Vidarabine Phosphate | 1990 |
Fludarabine phosphate therapy in other lymphoid malignancies.
Topics: Antimetabolites, Antineoplastic; Humans; Leukemia, Lymphoid; Lymphoma; Vidarabine Phosphate | 1990 |
Issues for the future development of fludarabine phosphate.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Evaluation; Humans; Infusions, Intravenous; Leukemia; Lymphoproliferative Disorders; Vidarabine Phosphate | 1990 |
Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Topics: Antimetabolites, Antineoplastic; Humans; Leukemia; Neoplasms; Vidarabine Phosphate | 1991 |
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
New chemotherapeutic agents for non-Hodgkin's lymphomas.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine Phosphate | 1991 |
New anticancer agents.
Topics: Adenine; Antibiotics, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Depsipeptides; Echinomycin; Epirubicin; Flavonoids; Guanidines; Humans; Idarubicin; Imides; Isoquinolines; Menogaril; Naphthalimides; Nogalamycin; Organophosphonates; Pentostatin; Peptides, Cyclic; Polymers; Vidarabine Phosphate | 1988 |
New anticancer agents.
Topics: Acetamides; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Flavonoids; Gallium; Humans; Mitolactol; Mitoxantrone; Organoplatinum Compounds; Pentostatin; Quinazolines; Ribavirin; Trimetrexate; Vidarabine Phosphate | 1987 |
Fludarabine phosphate: a new active agent in hematologic malignancies.
Topics: Animals; Clinical Trials as Topic; Hematologic Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Vidarabine Phosphate; Waldenstrom Macroglobulinemia | 1994 |
Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.
Topics: Animals; Antimetabolites, Antineoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Vidarabine Phosphate | 1994 |
Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions.
Topics: Antimetabolites, Antineoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Survival Rate; Vidarabine Phosphate | 1993 |
Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Vidarabine Phosphate; Waldenstrom Macroglobulinemia | 1993 |
New initiatives with fludarabine monophosphate in hematologic malignancies.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Hematologic Diseases; Humans; Neoplasms; Remission Induction; Vidarabine Phosphate | 1993 |
Tumor lysis syndrome induced by fludarabine monophosphate: a case report.
Topics: Acute Kidney Injury; Allopurinol; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluid Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Middle Aged; Sodium Bicarbonate; Tumor Lysis Syndrome; Vidarabine Phosphate | 1996 |
Why do drugs work in CLL?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine Phosphate | 1996 |
Fludarabine phosphate in lymphoma: an important new therapeutic agent.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Multiple Myeloma; Vidarabine Phosphate; Waldenstrom Macroglobulinemia | 1996 |
Purine nucleoside analogs in indolent non-Hodgkin's lymphoma.
Topics: Adenosine Deaminase Inhibitors; Antibiotics, Antineoplastic; Cladribine; Humans; Lymphoma; Pentostatin; Vidarabine Phosphate | 2000 |
Cellular and clinical pharmacology of fludarabine.
Topics: Antineoplastic Agents; Biological Availability; Deoxycytidine Kinase; DNA (Cytosine-5-)-Methyltransferases; Drug Evaluation, Preclinical; Humans; Leukemia; Lymphoma; Phosphorylation; Vidarabine; Vidarabine Phosphate | 2002 |
Infectious complications of purine analog therapy.
Topics: Antimetabolites, Antineoplastic; Cladribine; Humans; Immune Tolerance; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine Phosphate | 2001 |
Successful treatment of mu-heavy chain disease with fludarabine monophosphate: a case report.
Topics: Antimetabolites, Antineoplastic; Female; Heavy Chain Disease; Humans; Middle Aged; Radiography; Splenomegaly; Thrombocytopenia; Vidarabine Phosphate | 2004 |
Traditional treatment approaches in B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Humans; Lymphoma, B-Cell; Neoplasm Staging; Risk Assessment; Treatment Outcome; Vidarabine Phosphate | 2003 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
46 trial(s) available for vidarabine phosphate and fludarabine phosphate
| Article | Year |
|---|---|
Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Treatment Outcome; Vidarabine Phosphate | 1992 |
Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. An Illinois Cancer Center study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Vidarabine Phosphate | 1992 |
Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Drug Evaluation; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Mycosis Fungoides; Vidarabine Phosphate | 1990 |
A comprehensive phase I and II clinical investigation of fludarabine phosphate.
Topics: Adult; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Evaluation; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Neoplasms; Vidarabine Phosphate | 1990 |
Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; United States; Uterine Cervical Neoplasms; Vidarabine Phosphate | 1990 |
Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Child, Preschool; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine Phosphate | 1990 |
Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Topics: Antimetabolites, Antineoplastic; Humans; Leukemia; Neoplasms; Vidarabine Phosphate | 1991 |
Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Remission Induction; Survival Rate; Vidarabine Phosphate | 1991 |
Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Vidarabine Phosphate | 1991 |
Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group Study.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Evaluation; Female; Hematologic Diseases; Humans; Middle Aged; Uterine Neoplasms; Vidarabine Phosphate | 1991 |
Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
Topics: Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine; Vidarabine Phosphate | 1991 |
Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Drug Evaluation; Female; Humans; Male; Middle Aged; Remission Induction; Vidarabine Phosphate | 1991 |
A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine Phosphate | 1991 |
Phase II evaluation of fludarabine in patients with metastatic breast cancer: a Southeastern Cancer Study Group trial.
Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Middle Aged; Neoplasm Metastasis; Vidarabine Phosphate | 1986 |
Phase II study of fludarabine phosphate for gastric adenocarcinoma. An Illinois Cancer Center trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Injections, Intravenous; Male; Middle Aged; Stomach Neoplasms; Vidarabine Phosphate | 1994 |
A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma.
Topics: Antimetabolites, Antineoplastic; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Sarcoma; Sleep Stages; Vidarabine Phosphate | 1994 |
A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Chlorambucil; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine Phosphate | 1993 |
Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adult; Aged; Agranulocytosis; Antimetabolites, Antineoplastic; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Treatment Outcome; Vidarabine Phosphate | 1996 |
Fludarabine in chronic leukaemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Doxorubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prednisone; Vidarabine Phosphate | 1996 |
Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to sustain response.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Vidarabine Phosphate | 1996 |
Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.
Topics: Adult; Antimetabolites, Antineoplastic; Clinical Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; National Institutes of Health (U.S.); Survival Analysis; Treatment Outcome; United States; Vidarabine Phosphate | 1997 |
Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine Phosphate | 1998 |
Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Vidarabine Phosphate; Waldenstrom Macroglobulinemia | 1999 |
[The use of fludarabine phosphate (Fludara) to treat chronic B-cell lymphocytic leukemia and non-Hodgkin's lymphoma resistant to standard chemotherapy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Treatment Outcome; Vidarabine Phosphate | 1998 |
[Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Blood Cell Count; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Thrombocytopenia; Vidarabine Phosphate | 1999 |
Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Vidarabine Phosphate | 1999 |
[Phase II clinical study of SH L 573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine Phosphate | 1999 |
FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pilot Projects; Recurrence; Salvage Therapy; Survival Rate; Vidarabine Phosphate | 2000 |
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Hospitalization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Neoplasm Staging; Phosphoramide Mustards; Prednisone; Prognosis; Proportional Hazards Models; Sample Size; Survival Rate; Time Factors; Vidarabine Phosphate; Vincristine | 2001 |
Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Disease Progression; Disease-Free Survival; Drug Evaluation; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vidarabine Phosphate | 2001 |
The bioavailability of oral fludarabine phosphate is unaffected by food.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vidarabine Phosphate | 2001 |
Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Middle Aged; Recombinant Proteins; Remission Induction; Vidarabine Phosphate | 2002 |
Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Quality of Life; Remission Induction; Retrospective Studies; Safety; Survival Rate; Treatment Outcome; Vidarabine Phosphate | 2004 |
Fludarabine phosphate-CVP in patients over 60 years of age with advanced, low-grade and follicular lymphoma: a dose-finding study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lymphoma, Follicular; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Survival Analysis; Treatment Outcome; Vidarabine Phosphate; Vincristine | 2005 |
Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Vidarabine Phosphate | 2006 |
Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Recurrence; Vidarabine Phosphate | 2006 |
Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Infant; Male; Melphalan; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine Phosphate | 2006 |
Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Prospective Studies; Vidarabine Phosphate; Vincristine | 2006 |
High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Transplantation Conditioning; Vidarabine Phosphate | 2006 |
High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia.
Topics: Adult; Aged; Biomarkers; Creatinine; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine Phosphate | 2008 |
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Treatment Outcome; Vidarabine Phosphate; Young Adult | 2009 |
High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.
Topics: Adult; Aged; Drug Monitoring; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Metabolic Clearance Rate; Middle Aged; Neutrophil Infiltration; Prodrugs; Renal Insufficiency; Risk Factors; Survival Analysis; Transplantation Conditioning; Vidarabine; Vidarabine Phosphate; Young Adult | 2011 |
Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine Phosphate | 2011 |
Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytosis; Male; Middle Aged; Staurosporine; Treatment Outcome; Vidarabine Phosphate | 2011 |
A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Pharmacological; Busulfan; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pilot Projects; Proportional Hazards Models; Recurrence; Survival Rate; Vidarabine Phosphate | 2012 |
A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.
Topics: Adult; Aged; Area Under Curve; Biomarkers, Pharmacological; Cyclophosphamide; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Pilot Projects; Transplantation Conditioning; Vidarabine Phosphate; Young Adult | 2013 |
138 other study(ies) available for vidarabine phosphate and fludarabine phosphate
| Article | Year |
|---|---|
Fludarabine phosphate (Fludara).
Topics: Antimetabolites, Antineoplastic; Humans; Vidarabine Phosphate | 1992 |
Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Humans; Male; Pulmonary Fibrosis; Respiratory Insufficiency; Vidarabine Phosphate | 1992 |
From the Food and Drug Administration.
Topics: Arabinonucleotides; Blepharospasm; Botulinum Toxins; Drug Industry; Eyelid Diseases; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Orphan Drug Production; Strabismus; Tampons, Surgical; Vidarabine Phosphate | 1990 |
Fludarabine therapy in macroglobulinemic lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Female; Humans; Infusions, Intravenous; Lymphoma; Macroglobulins; Male; Middle Aged; Vidarabine Phosphate; Waldenstrom Macroglobulinemia | 1990 |
Adenosine receptors and modulation of natural killer cell activity by purine nucleosides.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Cell Line; Cytotoxicity, Immunologic; Deoxyadenosines; Humans; In Vitro Techniques; Killer Cells, Natural; Kinetics; Male; Mice; Mice, Inbred C3H; Receptors, Purinergic; Ribonucleotides; Spleen; Tubercidin; Tumor Cells, Cultured; Vidarabine Phosphate | 1990 |
Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced head and neck cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Drug Evaluation; Head and Neck Neoplasms; Humans; Middle Aged; Vidarabine Phosphate | 1990 |
Purine nucleoside modulation of functions of human lymphocytes.
Topics: B-Lymphocytes; Cytotoxicity, Immunologic; Humans; In Vitro Techniques; Killer Cells, Natural; Lymphocyte Activation; Lymphocytes; Phytohemagglutinins; Pokeweed Mitogens; Purine Nucleosides; Staphylococcus aureus; Tubercidin; Vidarabine Phosphate | 1990 |
Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study.
Topics: Adult; Aged; Agranulocytosis; Antimetabolites, Antineoplastic; Arabinonucleotides; Drug Administration Schedule; Drug Evaluation; Humans; Middle Aged; Multiple Myeloma; Vidarabine Phosphate | 1990 |
Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Cytomegalovirus Infections; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Pneumonia, Pneumocystis; Vidarabine Phosphate | 1990 |
Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate.
Topics: Acute Kidney Injury; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Metastasis; Male; Tumor Lysis Syndrome; Vidarabine Phosphate | 1990 |
Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity.
Topics: Aphidicolin; Arabinonucleotides; Cell Line; Cell Survival; Clone Cells; Diterpenes; DNA Replication; DNA-Directed DNA Polymerase; Guanosine Monophosphate; Humans; Kinetics; Nucleic Acid Synthesis Inhibitors; Vidarabine; Vidarabine Phosphate | 1990 |
Fludarabine monophosphate for prolymphocytic leukaemia.
Topics: Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Drug Administration Schedule; Humans; Leukemia, Prolymphocytic; Male; Remission Induction; Vidarabine Phosphate | 1990 |
Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells.
Topics: Antineoplastic Agents; Cell Division; Deferoxamine; Drug Synergism; Edetic Acid; Gallium; Humans; Iron; Iron Chelating Agents; Leukemia, Promyelocytic, Acute; Tumor Cells, Cultured; Vidarabine Phosphate | 1990 |
Role of natural killer cells in the modulation of primary antibody production by purine nucleosides and their analogs.
Topics: Animals; Antibody Formation; Killer Cells, Natural; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Pentostatin; Purine Nucleosides; T-Lymphocytes, Regulatory; Tubercidin; Vidarabine Phosphate | 1990 |
Fludarabine phosphate--looking forward.
Topics: Antimetabolites, Antineoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Vidarabine Phosphate | 1990 |
Fludarabine phosphate: an effective therapy for lymphoid malignancies.
Topics: Antimetabolites, Antineoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Vidarabine Phosphate | 1990 |
Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Drug Evaluation; Humans; Injections, Intravenous; Multivariate Analysis; Neoplasms; Vidarabine; Vidarabine Phosphate | 1990 |
Fludarabine phosphate therapy of non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nervous System Diseases; Remission Induction; Survival Rate; Vidarabine Phosphate | 1990 |
Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis.
Topics: Adult; Antimetabolites, Antineoplastic; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Pulmonary Fibrosis; Risk Factors; Vidarabine Phosphate | 1990 |
Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate.
Topics: Aphidicolin; Arabinofuranosylcytosine Triphosphate; Deoxyguanine Nucleotides; Diterpenes; DNA Primase; DNA-Directed DNA Polymerase; DNA, Neoplasm; Humans; Leukemia; RNA; RNA Nucleotidyltransferases; Tumor Cells, Cultured; Vidarabine Phosphate | 1991 |
Fludarabine phosphate in refractory hairy cell leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Humans; Leukemia, Hairy Cell; Male; Vidarabine Phosphate | 1991 |
Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia.
Topics: Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Opportunistic Infections; Pneumonia, Pneumocystis; Vidarabine Phosphate | 1991 |
From the Food and Drug Administration.
Topics: Antimetabolites, Antineoplastic; Drug Labeling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Sepsis; Tablets; Transfusion Reaction; United States; United States Food and Drug Administration; Vidarabine Phosphate; Yersinia enterocolitica; Yersinia Infections | 1991 |
Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Evaluation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Vidarabine Phosphate | 1991 |
A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Drug Therapy; Fluorescent Dyes; Humans; Inactivation, Metabolic; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Sensitivity and Specificity; Vidarabine Phosphate | 1991 |
Phase I clinical trial of fludarabine phosphate (F-ara-AMP).
Topics: Adult; Aged; Arabinonucleotides; Bone Marrow; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Vidarabine Phosphate | 1985 |
Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice.
Topics: Animals; Azacitidine; Brain Neoplasms; Cell Line; Cytarabine; Doxorubicin; Humans; Medulloblastoma; Melphalan; Mice; Mice, Nude; Mitoguazone; Neoplasm Transplantation; Nitrosourea Compounds; Skin Neoplasms; Vidarabine Phosphate | 1986 |
Phase I study of fludarabine (2-fluoro-ara-AMP).
Topics: Adult; Aged; Agranulocytosis; Antimetabolites, Antineoplastic; Arabinonucleotides; Breast Neoplasms; Choriocarcinoma; Drug Evaluation; Female; Humans; Middle Aged; Pregnancy; Rhabdomyosarcoma; Sarcoma, Ewing; Thrombocytopenia; Uterine Cervical Neoplasms; Uterine Neoplasms; Vidarabine Phosphate | 1985 |
Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.
Topics: Acute Disease; Adult; Arabinonucleotides; Central Nervous System; Drug Evaluation; Humans; Infusions, Parenteral; Leukemia; Leukemia, Lymphoid; Middle Aged; Nervous System Diseases; Vidarabine Phosphate | 1986 |
Phase II trial of fludarabine in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Drug Evaluation; Female; Humans; Middle Aged; Ovarian Neoplasms; Vidarabine Phosphate | 1986 |
The potentiation of radiation response on murine tumor by fludarabine phosphate.
Topics: Animals; Arabinonucleotides; Fibrosarcoma; Male; Mice; Mice, Inbred BALB C; Radiotherapy Dosage; Time Factors; Vidarabine Phosphate | 1986 |
Pharmacologic analysis of the ip administration of fludarabine phosphate in the swine.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleotides; Ascitic Fluid; Chromatography, High Pressure Liquid; Injections, Intraperitoneal; Kinetics; Swine; Vidarabine Phosphate | 1986 |
Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assay.
Topics: Agar; Arabinonucleotides; Bone Marrow Cells; Cisplatin; Clone Cells; Colony-Forming Units Assay; Culture Media; Culture Techniques; Doxorubicin; Female; Genital Neoplasms, Female; Humans; Ovarian Neoplasms; Vidarabine Phosphate | 1986 |
Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Arabinonucleotides; Carcinoma; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Vidarabine Phosphate | 1986 |
Pharmacokinetic study of fludarabine phosphate (NSC 312887).
Topics: Agranulocytosis; Antimetabolites, Antineoplastic; Arabinonucleotides; Biotransformation; Chromatography, High Pressure Liquid; Creatinine; Female; Humans; Kinetics; Male; Metabolic Clearance Rate; Middle Aged; Vidarabine Phosphate | 1986 |
Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study.
Topics: Acidosis; Adult; Arabinonucleotides; Blindness; Brain Diseases; Coma; Demyelinating Diseases; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Middle Aged; Vidarabine Phosphate | 1986 |
Central nervous system toxicity of fludarabine phosphate.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Blindness; Brain Diseases; Central Nervous System Diseases; Child; Drug Evaluation; Electroencephalography; Female; Humans; Leukemia; Male; Middle Aged; Tomography, X-Ray Computed; Vidarabine Phosphate; Vision Disorders | 1986 |
Central nervous system toxicity with fludarabine.
Topics: Adult; Aged; Arabinonucleotides; Autopsy; Central Nervous System Diseases; Dose-Response Relationship, Drug; Female; Humans; Male; Time Factors; Vidarabine Phosphate | 1986 |
9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; DNA; Humans; Kinetics; Leukemia; Lymphoma; Vidarabine Phosphate | 1986 |
Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity.
Topics: Adult; Aged; Antineoplastic Agents; Arabinonucleotides; Deoxycytidine Kinase; Drug Administration Schedule; Drug Evaluation; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Phosphotransferases; Prospective Studies; Vidarabine Phosphate | 1987 |
Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Carcinoma, Renal Cell; Female; Hematopoiesis; Humans; Kidney Neoplasms; Male; Middle Aged; Vidarabine Phosphate | 1987 |
Fludarabine phosphate. Phase II evaluation in advanced soft-tissue sarcomas.
Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Vidarabine Phosphate | 1987 |
Pulmonary toxicity associated with fludarabine monophosphate.
Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Humans; Leukemia, Lymphoid; Lung; Male; Middle Aged; Pulmonary Fibrosis; Vidarabine Phosphate | 1987 |
Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Arabinonucleotides; Carcinoma, Hepatocellular; Diagnosis-Related Groups; Drug Evaluation; Female; Humans; Liver Neoplasms; Male; Middle Aged; Vidarabine Phosphate | 1987 |
Phase II trial of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group Study.
Topics: Arabinonucleotides; Carcinoma, Squamous Cell; Drug Evaluation; Head and Neck Neoplasms; Hematopoiesis; Humans; Vidarabine Phosphate | 1987 |
Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Arabinonucleotides; Carcinoma; Colonic Neoplasms; Drug Evaluation; Humans; Middle Aged; Rectal Neoplasms; Vidarabine Phosphate | 1987 |
Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced ovarian cancer. A Southwest Oncology Group Study.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Arabinonucleotides; Drug Evaluation; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Vidarabine Phosphate | 1988 |
Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Nervous System; Vidarabine Phosphate | 1988 |
Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Breast Neoplasms; Drug Evaluation; Female; Humans; Middle Aged; Vidarabine Phosphate | 1988 |
Evaluation of fludarabine phosphate in small cell carcinoma. A Southwest Oncology Group Study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Carcinoma, Small Cell; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Vidarabine Phosphate | 1988 |
Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Colonic Neoplasms; Drug Evaluation; Female; Humans; Male; Middle Aged; Rectal Neoplasms; Vidarabine Phosphate | 1988 |
Evaluation of fludarabine phosphate in patients with recurrent glioma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Brain Neoplasms; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Vidarabine Phosphate | 1988 |
Cytotoxic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5-monophosphate (fludarabine, NSC 312887) in a human tumor cloning system.
Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, Non-Hodgkin; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vidarabine Phosphate | 1988 |
Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Bone Marrow; Drug Evaluation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Remission Induction; Vidarabine Phosphate | 1988 |
Fludarabine therapy in chronic lymphocytic leukemia (CLL).
Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Texas; Vidarabine Phosphate | 1988 |
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Drug Evaluation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neutropenia; Prognosis; Thrombocytopenia; Vidarabine Phosphate | 1989 |
Pharmacodynamics and proposed mechanism of therapeutic action and host toxicity of 9-beta-D-arabinofuranosyl-2-fluoroadenine monophosphate (F-araAMP) in P388 murine leukemia-bearing mice.
Topics: Animals; Arabinonucleotides; Bone Marrow; DNA; Half-Life; Intestinal Mucosa; Lethal Dose 50; Leukemia P388; Leukemia, Experimental; Male; Mice; Mice, Inbred Strains; Vidarabine Phosphate | 1989 |
Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arabinonucleotides; Carcinoma, Renal Cell; Drug Evaluation; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Vidarabine Phosphate | 1989 |
Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Drug Evaluation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Vidarabine Phosphate | 1989 |
Metabolism of 9-beta-D-arabinosyl-2-fluoroadenine-5'-phosphate by mice bearing P388 leukemia.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Arabinonucleotides; DNA; DNA, Neoplasm; Female; Leukemia P388; Leukemia, Experimental; Mice; Mice, Inbred DBA; Vidarabine Phosphate | 1983 |
Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
Topics: Adenocarcinoma; Arabinonucleotides; Drug Evaluation; Female; Humans; Kinetics; Lung Neoplasms; Male; Neoplasms; Vidarabine; Vidarabine Phosphate | 1984 |
Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite.
Topics: Adult; Aged; Arabinonucleotides; B-Lymphocytes; Drug Evaluation; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Leukocyte Count; Leukocytes; Male; Middle Aged; Neoplasms; T-Lymphocytes; Vidarabine Phosphate | 1984 |
Responses of human bone marrow progenitor cells to fluoro-ara-AMP, homoharringtonine, and elliptinium.
Topics: Alkaloids; Antineoplastic Agents; Arabinonucleotides; Cell Survival; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Ellipticines; Harringtonines; Hematopoietic Stem Cells; Homoharringtonine; Humans; In Vitro Techniques; Vidarabine Phosphate | 1984 |
Cross-resistance to purine analogs in hairy cell leukemia.
Topics: Antimetabolites, Antineoplastic; Cladribine; Drug Resistance; Humans; Leukemia, Hairy Cell; Pentostatin; Vidarabine Phosphate | 1994 |
2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine.
Topics: Aged; Antimetabolites, Antineoplastic; Cladribine; Drug Resistance; Female; Humans; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine Phosphate; Waldenstrom Macroglobulinemia | 1994 |
Lysis pneumonopathy associated with the use of fludarabine phosphate.
Topics: Adult; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Respiratory Insufficiency; Tumor Lysis Syndrome; Vidarabine Phosphate | 1994 |
2-Chlorodeoxyadenosine for multiple myeloma.
Topics: Antimetabolites, Antineoplastic; Cladribine; DNA Damage; Humans; Multiple Myeloma; Vidarabine Phosphate | 1993 |
Severe immunodeficiency in patients treated with fludarabine monophosphate.
Topics: Adult; Aged; Bone Marrow; Female; Humans; Immunoglobulins; Immunologic Deficiency Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; T-Lymphocyte Subsets; Vidarabine Phosphate | 1993 |
Anesthesia not related to fludarabine toxicity.
Topics: Anesthesia, General; Brain Diseases; Humans; Vidarabine Phosphate | 1993 |
Fludarabine phosphate and 2-chlorodeoxyadenosine: immunosuppressive DNA synthesis inhibitors with potential application in islet allo- and xenotransplantation.
Topics: Animals; Cladribine; Diabetes Mellitus, Experimental; DNA; Graft Survival; Humans; Immunosuppressive Agents; Islets of Langerhans Transplantation; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Lymphocyte Depletion; Rats; Rats, Inbred Lew; Rats, Inbred WF; Transplantation, Heterologous; Transplantation, Homologous; Vidarabine Phosphate | 1995 |
Fatal bone marrow necrosis following fludarabine administration in a patient with indolent lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Bone Marrow; Eosinophils; Fatal Outcome; Humans; Lymphoma, Non-Hodgkin; Male; Necrosis; Vidarabine Phosphate | 1995 |
Two new DNA synthesis inhibitors with potent immunosuppressive activity prolong allograft and xenograft survival in small and large animals.
Topics: Animals; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line; Cladribine; Diabetes Mellitus, Experimental; Graft Survival; Humans; Immunosuppressive Agents; Islets of Langerhans Transplantation; Lymphocyte Activation; Lymphocyte Depletion; Macaca fascicularis; Rats; Rats, Inbred Lew; Rats, Inbred WF; Skin Transplantation; Species Specificity; Swine; T-Lymphocytes; Transplantation, Heterologous; Transplantation, Homologous; Vidarabine Phosphate | 1996 |
Fludarabine phosphate: A DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; B-Lymphocytes; Bone Marrow; Bone Marrow Cells; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Division; DNA; Endonucleases; Graft Survival; Humans; Immunization; Immunosuppressive Agents; Leukocytes, Mononuclear; Leukopenia; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Lymphocyte Depletion; Macaca fascicularis; Mitogens; Neutropenia; Papio; Phytohemagglutinins; Skin Transplantation; Swine; T-Lymphocytes; Vidarabine Phosphate | 1996 |
Successful treatment of Sézary syndrome with lymphomatous transformation to large cell lymphoma with fludarabine phosphate.
Topics: Aged; Antimetabolites, Antineoplastic; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Sezary Syndrome; Skin Neoplasms; Vidarabine Phosphate | 1996 |
Fludarabine monophosphate as salvage for refractory chronic lymphocytic leukaemia.
Topics: Antimetabolites, Antineoplastic; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Salvage Therapy; South Africa; Vidarabine Phosphate | 1996 |
Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Antimetabolites, Antineoplastic; Drug Carriers; Drug Delivery Systems; Erythrocytes; Humans; Kinetics; Phosphorylation; Vidarabine; Vidarabine Phosphate | 1996 |
Determination of fludarabine phosphate in human plasma using reversed phase high-performance liquid chromatography.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Humans; Magnetic Resonance Spectroscopy; Spectrophotometry, Ultraviolet; Vidarabine Phosphate | 1996 |
[Peritoneal tuberculosis in a patient with chronic lymphatic leukemia in treatment with fludarabine].
Topics: Adenosine Deaminase; Aged; Biomarkers; False Negative Reactions; Fatal Outcome; Female; Humans; Immunity, Cellular; Immunocompromised Host; Opportunistic Infections; Peritonitis, Tuberculous; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tuberculin Test; Vidarabine Phosphate | 1996 |
[Fludarabine monophosphate in the treatment of patients with advanced stages of chronic B-cell lymphatic leukemia resistant to conventional chemotherapy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Vidarabine Phosphate | 1997 |
In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase.
Topics: Animals; Antimetabolites, Antineoplastic; Escherichia coli; Genetic Therapy; Genetic Vectors; Glioma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Prodrugs; Purine Nucleosides; Purine-Nucleoside Phosphorylase; Retroviridae; Vidarabine Phosphate | 1997 |
Autoimmune thrombocytopenia after six cycles of fludarabine phosphate in a patient with chronic lymphocytic leukemia.
Topics: Aged; Autoimmune Diseases; Drug Administration Schedule; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Thrombocytopenia; Vidarabine Phosphate | 1997 |
Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia.
Topics: Antigens, CD19; Antimetabolites, Antineoplastic; Apoptosis; B-Lymphocytes; CD3 Complex; CD4 Antigens; CD8 Antigens; Cell Cycle; Cyclosporine; Flow Cytometry; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Proto-Oncogene Proteins c-bcl-2; T-Lymphocytes; Tumor Cells, Cultured; Vidarabine Phosphate | 1998 |
More on purine analog-induced apoptosis in B cell chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine Phosphate | 1998 |
Radiation rendered more cytotoxic by fludarabine monophosphate in a human oropharynx carcinoma cell-line than in fetal lung fibroblasts.
Topics: Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Fetus; Fibroblasts; Humans; Lung; Oropharyngeal Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Vidarabine Phosphate | 1998 |
Re: V.I. Avramis et al., Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a Phase I/II study in pediatric patients with relapsed leukemias. Clin. Can
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Leukemia; Terminology as Topic; Vidarabine; Vidarabine Phosphate | 1999 |
Synthesis and antiproliferative potency of 9-beta-D-arabinofuranosyl-2-fluoroadenine phospholipid adducts.
Topics: Antimetabolites, Antineoplastic; Cell Division; HL-60 Cells; Humans; Tumor Cells, Cultured; Vidarabine Phosphate | 1999 |
Astrovirus enteritis in a chronic lymphocytic leukemia patient treated with fludarabine monophosphate.
Topics: Antimetabolites, Antineoplastic; Astroviridae Infections; Feces; Gastroenteritis; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mamastrovirus; Microscopy, Electron; Middle Aged; Vidarabine Phosphate | 2000 |
The prophylactic potential of fludarabine monophosphate in graft-versus-host disease after bone marrow transplantation in murine models.
Topics: Animals; Bone Marrow Transplantation; Disease Models, Animal; Graft Survival; Graft vs Host Disease; Histocompatibility; Immunosuppressive Agents; Major Histocompatibility Complex; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Minor Histocompatibility Loci; Survival Rate; Transplantation Chimera; Vidarabine Phosphate; Weight Loss | 2000 |
In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Hydroxyurea; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Methotrexate; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine; Vidarabine Phosphate; Vincristine | 2000 |
A 3'-5' exonuclease in human leukemia cells: implications for resistance to 1-beta -D-arabinofuranosylcytosine and 9-beta -D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate.
Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Cell Nucleus; Cells, Cultured; Cytidine Monophosphate; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Exodeoxyribonuclease V; Exodeoxyribonucleases; Exonucleases; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphocytes; Magnesium; Neoplasm Proteins; Potassium Chloride; Protein Biosynthesis; Time Factors; Transcription, Genetic; Tumor Cells, Cultured; Up-Regulation; Vidarabine Phosphate | 2000 |
Inhibition of murine AIDS by alternate administration of azidothymidine and fludarabine monophosphate.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Bone Marrow; DNA, Viral; Drug Therapy, Combination; Female; Flow Cytometry; Immunoglobulin G; Immunophenotyping; Immunosuppressive Agents; Injections, Intraperitoneal; Leukemia Virus, Murine; Liver; Lymph Nodes; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Proviruses; Spleen; Vidarabine Phosphate; Zidovudine | 2000 |
Gene expression in chronic lymphocytic leukemia B cells and changes during induction of apoptosis.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Transformation, Viral; Gene Expression Regulation, Neoplastic; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine Phosphate | 2000 |
The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage.
Topics: Antineoplastic Agents; Apoptosis; Arabinonucleotides; Caspases; DNA; DNA Damage; Enzyme Activation; Humans; Leukemia, Myeloid; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; S Phase; Tumor Cells, Cultured; U937 Cells; Vidarabine; Vidarabine Phosphate | 2000 |
Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models.
Topics: Adenine; Animals; Avian Sarcoma Viruses; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Male; Mastadenovirus; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms, Experimental; Prodrugs; Prostatic Neoplasms; Purine-Nucleoside Phosphorylase; Transduction, Genetic; Transplantation, Heterologous; Tumor Cells, Cultured; Vidarabine Phosphate | 2002 |
Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy.
Topics: Animals; Bone Marrow Transplantation; Cyclophosphamide; Diabetes Mellitus, Type 1; Female; Graft Survival; Immune Tolerance; Immunosuppressive Agents; Islets of Langerhans Transplantation; Major Histocompatibility Complex; Male; Mice; Mice, Inbred NOD; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine Phosphate | 2002 |
Corticosteroid responsive fludarabine pulmonary toxicity.
Topics: Antimetabolites, Antineoplastic; Female; Glucocorticoids; Humans; Lung Diseases; Middle Aged; Vidarabine Phosphate; Waldenstrom Macroglobulinemia | 2002 |
The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Metabolic Clearance Rate; Middle Aged; Prospective Studies; Vidarabine Phosphate | 2002 |
Leg ulcers associated with cryoglobulinemia: clinical study of 15 patients and response to treatment.
Topics: Adult; Aged; Cryoglobulinemia; Cyclophosphamide; Female; France; Humans; Infusions, Intravenous; Interferon-alpha; Leg Ulcer; Male; Medical Records; Middle Aged; Plasma Exchange; Prednisone; Retrospective Studies; Vidarabine Phosphate; Wound Healing | 2003 |
A substantial level of donor hematopoietic chimerism is required to protect donor-specific islet grafts in diabetic NOD mice.
Topics: Animals; Bone Marrow; Cyclophosphamide; Diabetes Mellitus, Type 1; Female; Immunosuppressive Agents; Islets of Langerhans Transplantation; Lymphocytes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine Phosphate | 2003 |
Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Topics: Adamantane; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Hydroquinones; Imatinib Mesylate; Leukemia-Lymphoma, Adult T-Cell; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vascular Endothelial Growth Factor A; Vidarabine Phosphate | 2003 |
Successful allogeneic leg transplantation in rats in conjunction with intra-bone marrow injection of donor bone marrow cells.
Topics: Animals; Bone Marrow Transplantation; Female; Graft Survival; Graft vs Host Disease; Hindlimb; Immunosuppressive Agents; Rats; Rats, Inbred BN; Rats, Inbred F344; Transplantation Conditioning; Transplantation, Homologous; Vidarabine Phosphate; Whole-Body Irradiation | 2003 |
Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease.
Topics: Adenocarcinoma; Adenoviridae; Animals; Animals, Genetically Modified; Antimetabolites, Antineoplastic; Disease Models, Animal; Escherichia coli; Female; Genetic Therapy; Infusions, Parenteral; Male; Mice; Mice, Inbred C57BL; Prodrugs; Prostate; Prostatic Neoplasms; Purine-Nucleoside Phosphorylase; Survival Analysis; Vidarabine Phosphate | 2004 |
Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antimetabolites, Antineoplastic; Cohort Studies; Female; Humans; Lymphocyte Subsets; Male; Middle Aged; Mycosis Fungoides; Phenotype; Photopheresis; Pilot Projects; Sezary Syndrome; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vidarabine Phosphate | 2004 |
The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Caspases; Cell Cycle; Cell Cycle Proteins; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; Humans; Jurkat Cells; Leukemia; MAP Kinase Kinase Kinase 1; MAP Kinase Kinase Kinases; Mitochondria; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reactive Oxygen Species; S Phase; Tumor Necrosis Factor-alpha; U937 Cells; Vidarabine Phosphate | 2004 |
Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Replication; Drug Evaluation, Preclinical; Genetic Therapy; Genetic Vectors; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prodrugs; Prostatic Neoplasms; Purine-Nucleoside Phosphorylase; Vidarabine Phosphate | 2004 |
Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Drug; Escherichia coli; Genetic Therapy; Genetic Vectors; Glioma; Humans; Lentivirus; Mice; Mice, Nude; Moloney murine leukemia virus; Purine-Nucleoside Phosphorylase; Transfection; Vidarabine Phosphate; Xenograft Model Antitumor Assays | 2004 |
Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cattle; Cell Proliferation; Disease Models, Animal; Genetic Therapy; Genetic Vectors; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Prodrugs; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Purine-Nucleoside Phosphorylase; Transduction, Genetic; Vidarabine Phosphate | 2004 |
Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Up-Regulation; Vidarabine Phosphate | 2005 |
Fludarabine phosphate may be useful in the treatment of graft-versus-host disease.
Topics: Animals; Antimetabolites; Antineoplastic Agents; CD4 Lymphocyte Count; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukocyte Reduction Procedures; Leukopenia; Mice; Stem Cell Transplantation; T-Lymphocyte Subsets; Vidarabine Phosphate | 2005 |
In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis.
Topics: Aged; Antineoplastic Agents; Apoptosis; Arginine; Chlorambucil; Codon; Cyclophosphamide; DNA Mutational Analysis; Doxorubicin; Drug Resistance, Neoplasm; Female; Gamma Rays; Gene Expression Regulation, Neoplastic; Genes, p53; Homozygote; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Mutation; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Polymorphism, Single-Stranded Conformational; Prognosis; Proline; Vidarabine Phosphate; Vincristine | 2005 |
Pulmonary non-caseating granuloma in Waldenström macroglobulinemia.
Topics: Antimetabolites, Antineoplastic; Humans; Male; Middle Aged; Plasma Cell Granuloma, Pulmonary; Radiography; Treatment Outcome; Vidarabine Phosphate; Waldenstrom Macroglobulinemia | 2005 |
Contrast-enhanced MR imaging in the indirect monitoring of drug release from an interstitial depot.
Topics: Animals; Antimetabolites, Antineoplastic; Contrast Media; Delayed-Action Preparations; Drug Monitoring; Gadolinium DTPA; Injections, Subcutaneous; Liposomes; Magnetic Resonance Imaging; Rats; Vidarabine Phosphate | 2005 |
Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imaging.
Topics: Algorithms; Animals; Antimetabolites, Antineoplastic; Biological Availability; Contrast Media; Delayed-Action Preparations; Drug Delivery Systems; Drug Monitoring; Fluorine; Gadolinium DTPA; Hydrogen; Injections, Subcutaneous; Liposomes; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Rats; Rats, Wistar; Tissue Distribution; Vidarabine Phosphate | 2006 |
F-ara-AMP is a substrate of cytoplasmic 5'-nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation.
Topics: 5'-Nucleotidase; Chromatography, High Pressure Liquid; Cytoplasm; Humans; Kinetics; Magnetic Resonance Spectroscopy; Vidarabine; Vidarabine Phosphate | 2006 |
Subcutaneous Taenia crassiceps infection in a patient with non-Hodgkin's lymphoma.
Topics: Aged, 80 and over; Albendazole; Animals; Cyclophosphamide; Female; Humans; Immunocompromised Host; Larva; Lymphoma, Non-Hodgkin; Praziquantel; Subcutaneous Tissue; Taenia; Taeniasis; Vidarabine Phosphate | 2006 |
Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; DNA Replication; Escherichia coli; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; Humans; Leukemia Virus, Murine; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prodrugs; Purine-Nucleoside Phosphorylase; Transduction, Genetic; Transplantation, Heterologous; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vidarabine Phosphate | 2007 |
Multifocal extranodal mucosa-associated lymphoid tissue lymphoma affecting the larynx.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Diagnosis, Differential; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Humans; Laryngeal Neoplasms; Laryngoscopy; Lymphoma, B-Cell, Marginal Zone; Magnetic Resonance Imaging; Rituximab; Vidarabine Phosphate | 2007 |
The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Radiation-Sensitizing Agents; Vidarabine Phosphate | 2008 |
Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs.
Topics: Adenine Nucleotides; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Bone Marrow Cells; Cells, Cultured; Cladribine; Clofarabine; Granulocyte-Macrophage Progenitor Cells; HT29 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Models, Biological; Neoplasms; Treatment Outcome; Vidarabine Phosphate; Xenograft Model Antitumor Assays | 2009 |
Genzyme takes Campath bet.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Drug Industry; Granulocyte-Macrophage Colony-Stimulating Factor; Recombinant Proteins; Vidarabine Phosphate | 2009 |
A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients.
Topics: Adolescent; Adult; Aged; Blood Specimen Collection; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Models, Biological; Retrospective Studies; Time Factors; Transplantation Conditioning; Vidarabine Phosphate; Young Adult | 2009 |
Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.
Topics: Administration, Oral; Adult; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Half-Life; Heart Rate; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Chemical; Vidarabine; Vidarabine Phosphate | 2010 |
Critical review of the determination process by the Japanese reviewing authority in approving the additional efficacy of fludarabine phosphate.
Topics: Antimetabolites, Antineoplastic; Drug Approval; Hematopoietic Stem Cell Transplantation; Humans; Japan; Off-Label Use; Transplantation Conditioning; Vidarabine Phosphate | 2009 |
[Successful treatment of T-cell prolymphocytic leukemia (T-PLL) with fludarabine monophosphate].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Humans; Infusions, Intravenous; Leukemia, Prolymphocytic, T-Cell; Treatment Outcome; Vidarabine Phosphate | 2009 |
Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.
Topics: Animals; Antimetabolites, Antineoplastic; Escherichia coli; Genetic Therapy; Genetic Vectors; Glioma; Green Fluorescent Proteins; Humans; Injections, Intralesional; Injections, Subcutaneous; Mice; Mice, Nude; Prodrugs; Purine-Nucleoside Phosphorylase; Retroviridae; Vidarabine Phosphate | 2010 |
Cytotoxic activity of 2-Fluoro-ara-AMP and 2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arabinonucleotides; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cytotoxins; DNA, Neoplasm; Drug Delivery Systems; Drug Evaluation, Preclinical; Erythrocytes; Female; Flow Cytometry; Humans; Time Factors; Vidarabine Phosphate | 2010 |
Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase.
Topics: Adenine Phosphoribosyltransferase; Animals; Cell Line, Tumor; Escherichia coli; Genetic Therapy; Genetic Vectors; Humans; Mice; Prodrugs; Purine Nucleosides; Purine-Nucleoside Phosphorylase; Transplantation, Heterologous; Vidarabine Phosphate | 2011 |
Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy.
Topics: Animals; Arrestins; beta-Arrestins; Cell Death; Cell Line, Tumor; Escherichia coli; Gene Expression Regulation, Neoplastic; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; Humans; Male; Metribolone; Mice; Promoter Regions, Genetic; Prostatic Neoplasms; Purine-Nucleoside Phosphorylase; Rats; Vidarabine Phosphate | 2011 |
In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Bystander Effect; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Escherichia coli; Genetic Therapy; Genetic Vectors; Glioma; Humans; Injections, Intralesional; Mice; Mice, Nude; Prodrugs; Purine-Nucleoside Phosphorylase; Transfection; Transplantation, Heterologous; Vidarabine Phosphate | 2012 |
Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Proliferation; Drug Repositioning; Drug Synergism; Female; Gastrointestinal Stromal Tumors; High-Throughput Screening Assays; Humans; Imatinib Mesylate; Mice; Mice, Nude; Piperazines; Pyrimidines; Vidarabine Phosphate; Xenograft Model Antitumor Assays | 2014 |
Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Child; Cohort Studies; Half-Life; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Myeloid; Lymphocyte Count; Lymphopoiesis; Middle Aged; Models, Biological; Myeloproliferative Disorders; Reproducibility of Results; Retrospective Studies; Transplantation Conditioning; Vidarabine Phosphate; Young Adult | 2015 |
Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Aziridines; Bacterial Proteins; Bifidobacterium; Cell Line, Tumor; Drug Delivery Systems; Enzymes; Escherichia coli; Female; Lactobacillus; Lactococcus; Mice, Inbred BALB C; Neoplasms; Probiotics; Prodrugs; Tumor Burden; Vidarabine Phosphate | 2016 |
Using Gold Nanoparticles as Delivery Vehicles for Targeted Delivery of Chemotherapy Drug Fludarabine Phosphate to Treat Hematological Cancers.
Topics: Antineoplastic Agents; Cell Line, Tumor; Gold; Hematologic Neoplasms; Humans; Metal Nanoparticles; Microscopy, Electron, Transmission; Spectrophotometry, Ultraviolet; Vidarabine Phosphate | 2016 |
Glycodendrimer Nanocarriers for Direct Delivery of Fludarabine Triphosphate to Leukemic Cells: Improved Pharmacokinetics and Pharmacodynamics of Fludarabine.
Topics: Dendrimers; Drug Carriers; Humans; Leukemia; THP-1 Cells; U937 Cells; Vidarabine Phosphate | 2018 |
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
Topics: Adult; Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Mutation; Primary Myelofibrosis; Prognosis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine Phosphate | 2019 |
Peptidomimetic-based identification of FDA-approved compounds inhibiting IRE1 activity.
Topics: Cefoperazone; Cell Line, Tumor; Drug Approval; Endoplasmic Reticulum Stress; Endoribonucleases; Enzyme Inhibitors; Humans; Leucovorin; Methotrexate; Molecular Structure; Peptidomimetics; Protein Binding; Protein Domains; Protein Serine-Threonine Kinases; Signal Transduction; Unfolded Protein Response; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2021 |
5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis.
Topics: Antiviral Agents; Cell Line; COVID-19 Drug Treatment; Deoxyguanosine; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Microbial Sensitivity Tests; Nucleic Acid Synthesis Inhibitors; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Thionucleosides; Tubercidin; Vidarabine; Vidarabine Phosphate | 2022 |
A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers.
Topics: Androgen Antagonists; Carcinoma, Neuroendocrine; Cell Line, Tumor; Drug Repositioning; Humans; Male; N-Myc Proto-Oncogene Protein; Prostatic Neoplasms; Reactive Oxygen Species; Vidarabine Phosphate | 2022 |